Drug intelligence / Profile preview

PBI-203

Development stage: Preclinical
Lead developer: Protheragen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PBI-203 is a preclinical-stage bispecific antibody developed by Protheragen for the treatment of solid tumors. It is designed to simultaneously target Programmed Death-Ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF). By dual-targeting these pathways, PBI-203 aims to inhibit tumor immune evasion and suppress angiogenesis, potentially offering a synergistic therapeutic effect compared to monotherapies. The anti-PD-L1 component blocks the PD-1/PD-L1 checkpoint to restore T-cell activity, while the anti-VEGF component inhibits the formation of new blood vessels that support tumor growth.

Targets

CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on PBI-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBI-203.

Explore the full profile